TuHURA Biosciences, Inc. HURA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 43.77% | -- | -- | -- | 62.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.43% | -- | -- | -- | 44.86% |
| Operating Income | -40.43% | -- | -- | -- | -44.86% |
| Income Before Tax | -10.30% | -- | -- | -- | -60.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.30% | -- | -- | -- | -60.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.30% | -- | -- | -- | -60.20% |
| EBIT | -40.43% | -- | -- | -- | -44.86% |
| EBITDA | -40.47% | -- | -- | -- | -45.82% |
| EPS Basic | 49.38% | -- | -- | -- | -22.15% |
| Normalized Basic EPS | 36.10% | -- | -- | -- | -2.63% |
| EPS Diluted | 49.38% | -- | -- | -- | -22.04% |
| Normalized Diluted EPS | 36.10% | -- | -- | -- | -2.63% |
| Average Basic Shares Outstanding | 64.65% | -- | -- | -- | 49.69% |
| Average Diluted Shares Outstanding | 64.65% | -- | -- | -- | 49.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.81% | -- | -- | -- | -- |